|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-8-4
|
|
pubmed:abstractText |
The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2985-90
|
|
pubmed:dateRevised |
2010-10-20
|
|
pubmed:meshHeading |
pubmed-meshheading:20683043-Adult,
pubmed-meshheading:20683043-Aged,
pubmed-meshheading:20683043-Antimetabolites, Antineoplastic,
pubmed-meshheading:20683043-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20683043-Disease-Free Survival,
pubmed-meshheading:20683043-Drug Combinations,
pubmed-meshheading:20683043-Female,
pubmed-meshheading:20683043-Humans,
pubmed-meshheading:20683043-Lung Neoplasms,
pubmed-meshheading:20683043-Male,
pubmed-meshheading:20683043-Middle Aged,
pubmed-meshheading:20683043-Oxonic Acid,
pubmed-meshheading:20683043-Survival Rate,
pubmed-meshheading:20683043-Tegafur
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type.
|
|
pubmed:affiliation |
Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. n.yamamoto@scchr.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
